Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Teunissen, CE; Khalil, M.
Neurofilaments as biomarkers in multiple sclerosis.
Mult Scler. 2012; 18(5):552-556
Doi: 10.1177/1352458512443092
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Khalil Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Neurodegeneration is the correlate of disease progression in multiple sclerosis (MS) and thus biological biomarkers that sensitively reflect this process are much needed. Neurofilament protein subunits are potential cerebrospinal fluid (CSF) biomarkers for disease progression in MS. We argue that the neurofilament light subunit can reflect acute axonal damage mediated by inflammatory mechanisms and can imply prognostic value for conversion from clinically isolated syndrome (CIS) to definite MS. The neurofilament heavy subunit may rather reflect chronic irreversible damage and has prognostic value for disease progression or disability. The neurofilament intermediate subunit has not yet been studied. Recent studies showing higher neurofilament light or heavy subunit levels to be altered upon treatment regimes indicate their potential clinical value in monitoring treatment or side effects. Future studies should be aimed at the optimisation, standardisation and interlaboratory implementation of the assays and address the predictive value of these biomarkers.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Biological Markers - cerebrospinal fluid
- Disability Evaluation -
- Disease Progression -
- Humans -
- Multiple Sclerosis - cerebrospinal fluid
- Neurofilament Proteins - cerebrospinal fluid
- Predictive Value of Tests -
- Prognosis -
- Protein Subunits -
- Severity of Illness Index -
- Find related publications in this database (Keywords)
- Neurofilaments
- biomarkers
- disease progression
- treatment monitoring
- interlaboratory validation